Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ELANE | P08246 | 2/20 | 0.54 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 2/20 | 0.47 |
| ▸ | KLK1 | P06870 | 2/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | KLK8 | O60259 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | KLK4 | Q9Y5K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5581831 | 0.80 | LMNA (0.70) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL29592964 | 0.79 | LMNA (0.68) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL13538361 | 0.78 | LMNA (0.58) | LMNASMN1; SMN2ELANEPRTN3L3MBTL1 | |
| SCHEMBL3811564 | 0.77 | L3MBTL1 (0.80) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL5945564 | 0.77 | LMNA (0.57) | LMNASMN1; SMN2ELANEPRTN3L3MBTL1 | |
| SCHEMBL28046271 | 0.77 | TDP1 (0.66) | ELANEPRTN3L3MBTL1HTTTDP1 | |
| SCHEMBL14002292 | 0.76 | HTT (0.60) | LMNASMN1; SMN2ELANEPRTN3L3MBTL1 | |
| SCHEMBL4586916 | 0.76 | HTT (0.60) | LMNASMN1; SMN2ELANEPRTN3L3MBTL1 | |
| SCHEMBL8189834 | 0.76 | LMNA (0.63) | LMNASMN1; SMN2L3MBTL1MAPTHTT | |
| SCHEMBL9932446 | 0.76 | LMNA (0.63) | LMNASMN1; SMN2L3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1742642-B1 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1558613-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | disclosed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | LMNA 30/4885SMN1; SMN2 3377/4885ELANE 2868/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | LMNA 24/4885SMN1; SMN2 3976/4885ELANE 3088/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | LMNA 24/4885SMN1; SMN2 3976/4885ELANE 3088/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | LMNA 17/4885SMN1; SMN2 3403/4885ELANE 2910/4885 |
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | LMNA 3159/4885SMN1; SMN2 1271/4885ELANE 87/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | LMNA 2126/4885SMN1; SMN2 4116/4885ELANE 1963/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | LMNA 2126/4885SMN1; SMN2 4116/4885ELANE 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.